Developer docs
API playgroundTry for free, no card

Search company profiles

bialoom

Full company profile

uuid0004h3p

Namestring
bialoom
Legal namestring
bialoom
Websiteurl
bialoom.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

bialoom is a deep tech point-of-care diagnostics start-up established in 2018 and headquartered in Nicosia, Cyprus, operating at the intersection of silicon photonics, plasmonics, and in-vitro diagnostics. The company is developing biosensor-based devices intended to enable rapid diagnosis and treatment of severe infections and anaphylaxis at the point of need, with stated end users including hospital emergency departments, allergy clinics, and private medical practices. Primary customer use cases are tryptase quantification for anaphylaxis diagnosis and acute infection biomarker analysis.

The company's core offering is a proprietary silicon plasmo-photonic biosensor technology that uses plasmonic interferometric sensors on a micrometer-scale sensing area, capable of detecting multiple critical biomarkers from picoliter-scale analytes. Manufacturing leverages standard CMOS semiconductor processes to produce low-cost, multi-sensor biochips embedded in disposable cartridges, with two flagship diagnostic projects: MultiCare (a 2-year, small-scale project completed in June 2023 that validated plasmo-photonic biosensing as an in-vitro diagnostic device for acute infection analysis) and LOTTO (a higher-sensitivity tryptase detection prototype for rapid anaphylaxis diagnosis). The company has pursued AI/ML partnerships as a stated future capability to integrate personalized test outcomes with patient medical records, demographics, and medical statistics, though no implemented AI product is disclosed.

Bialoom is in pre-commercial stage with no disclosed revenue, customers, pricing, or active distribution channels. The business model centers on future sales of disposable biochip cartridges used with a proprietary point-of-care instrument, targeting institutional healthcare buyers via an enterprise field-sales motion. To date the company has been financed primarily through non-dilutive sources — the EU Horizon 2020 research and innovation programme (Grant Agreement No 888337, SepsiCare) and the Cyprus Research and Innovation Foundation Proof of Concept programme (Grant No CONCEPT/0618/0038, LOTTO) — with operational support from incubators Gravity Ventures / CyRIC and co-development relationships with AMO GmbH and RWTH Aachen.

Short descriptiontext

Bialoom is a Nicosia, Cyprus-based deep tech startup developing silicon plasmo-photonic biosensor technology for point-of-care diagnostics of severe infections and anaphylaxis, targeting emergency departments, allergy clinics, and private medical practices. The company is pre-commercial with proof-of-concept validated and grant-funded R&D in progress.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNicosia, Cyprus
HQ citystring
Nicosia
HQ countrystring
Cyprus
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, silicon photonics biosensors, plasmonic biochips, in-vitro diagnostic devices, anaphylaxis and sepsis testing
Industry2 codes
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Point-of-Care Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Disposable Diagnostic Cartridges
TypeHardware Sales
Description

Revenue expected from sale of disposable biochip cartridges for point-of-care diagnostics. The company is developing multi-functional biochips capable of quantifying biomarker signatures from patient blood for faster diagnosis and treatment of severe infections.

bialoom.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MultiCare
Description

In-vitro diagnostic device for analysis of acute infections at the point of care using plasmo-photonic biosensing technology. Small-scale 2-year project completed in June 2023.

bialoom.com
+1 more record
Core offering1 text field

Bialoom develops proprietary silicon plasmo-photonic biosensor technology delivered as multi-functional biochips embedded in disposable cartridges capable of quantifying complex biomarker signatures from patient blood. The company targets point-of-care diagnosis of acute infections and anaphylaxis at emergency departments, allergy clinics, hospitals, and private medical practices. Validated programs include MultiCare (acute infections, completed June 2023) and LOTTO (tryptase detection for anaphylaxis).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Point-of-care diagnosis without need for centralized lab equipment
Product overview1 text field

bialoom is a deep tech diagnostics company offering a unified portfolio built around proprietary silicon plasmo-photonic biosensor technology. The core technology powers multi-functional biochips embedded in disposable cartridges capable of quantifying complex biomarker signatures from patient blood. The product portfolio includes two validated diagnostic projects: MultiCare validated the technology for acute infection diagnostics at point of care, while LOTTO demonstrated a prototype for high-sensitivity tryptase detection for anaphylaxis diagnosis. Both products leverage the same underlying platform technology combining silicon photonics, plasmonics, and in-vitro diagnostics.

Product and service3 records
1MultiCare
CategoryIn-vitro diagnostic device for acute infections
Description

A plasmo-photonic biosensing in-vitro diagnostic device for analysis of acute infections at the point of care. The MultiCare program validated the underlying biosensor technology, optimized product design for market needs, and established the system proof of concept.

2LOTTO (Low-cost Optical biochip for diagnosis of anaphylaxis at The poinT Of care)
CategoryPoint-of-care anaphylaxis diagnostic prototype
Description

A high-sensitivity tryptase detection prototype system enabling rapid anaphylaxis diagnosis at the point of care, designed for use in emergency departments, allergy clinics, and private medical practices.

3Silicon Plasmo-Photonic Biosensor Disposable Cartridges
CategoryDisposable point-of-care diagnostic cartridges
Description

Proprietary multi-functional biochips embedded in disposable cartridges that quantify complex biomarker signatures from patient blood, intended to enable faster, evidence-based diagnosis and treatment of severe infections at the point of need.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

AMO GmbH is a technology partner. Nature of partnership involves collaboration on silicon photonics and biosensor development. AMO is listed as a partner on the company website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

RWTH Aachen University is listed as a partner. The partnership involves research collaboration related to biosensor technology development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1LumiraDx
TypeDirect peer
Description

Point-of-care diagnostics platform company combining microfluidic and immunoassay technologies on a single instrument with disposable test strips. Highly comparable to bialoom's POC, multi-analyte, disposable-cartridge strategy for acute and time-critical indications.

TypeBroad incumbent
Description

Major IVD player with a deep POC portfolio including Triage and Sofia rapid diagnostics used in emergency departments and clinics. Direct overlap with bialoom's anaphylaxis and acute-infection ED targets, and a likely employer/competitor for its core engineering talent.

3Abbott Point of Care
TypeBroad incumbent
Description

Established i-STAT and rapid diagnostics franchise serving emergency departments and physician offices. Represents both a primary competitor in POC and a source of comparable product-development experience via bialoom team member Kyle Hukari's prior role.

TypeDirect peer
Description

Developer of proprietary diagnostic biosensor platforms (T2MR) for sepsis and other bloodstream infections. Directly comparable use case (rapid sepsis diagnostics) and a precedent for a small company commercializing a novel biosensor-based IVD.

TypeEmerging player
Description

UK-based graphene-based biosensor company; bialoom Senior Scientist Serife Ustuner previously worked at Paragraf on surface functionalization. Comparable as a deep-tech biosensor startup targeting IVD and life-science markets.

TypeEmerging player
Description

Swiss POC diagnostics company using proprietary nanofluidic biosensor technology for rapid allergy (IgE), sepsis, and other panels. Closely aligned with bialoom on miniaturized, chip-based POC IVDs for anaphylaxis and acute infection.

TypeEmerging player
Description

Life-science instrumentation company focused on single-cell analysis, qPCR, and protein detection; bialoom's Kyle Hukari previously directed engineering there. Comparable as a developer of consumable-driven analytical instruments using semiconductor-like manufacturing.

TypeBroad incumbent
Description

Established molecular diagnostics franchise (GeneXpert) used in hospitals and EDs for rapid syndromic testing including sepsis and infectious disease. Sets the performance and workflow bar bialoom's POC biosensor must match or beat.

TypeBroad incumbent
Description

Global IVD leader with extensive POC and central-lab immunoassay menus for sepsis, cardiac, and allergy markers. Defines the cost, regulatory, and channel benchmark bialoom must compete against in EDs and allergy clinics.

TypeOthers
Description

Specializes in critical measurement and sensor-based products including biological indicators and sterilization monitoring. Adjacent as a sensor/measurement instrumentation peer with a similar deep-tech-to-commercial trajectory.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

bialoom

Point-of-Care Diagnosticsbialoom.com

Bialoom is a Nicosia, Cyprus-based deep tech startup developing silicon plasmo-photonic biosensor technology for point-of-care diagnostics of severe infections and anaphylaxis, targeting emergency departments, allergy clinics, and private medical practices. The company is pre-commercial with proof-of-concept validated and grant-funded R&D in progress.

What bialoom does

bialoom is a deep tech point-of-care diagnostics start-up established in 2018 and headquartered in Nicosia, Cyprus, operating at the intersection of silicon photonics, plasmonics, and in-vitro diagnostics. The company is developing biosensor-based devices intended to enable rapid diagnosis and treatment of severe infections and anaphylaxis at the point of need, with stated end users including hospital emergency departments, allergy clinics, and private medical practices. Primary customer use cases are tryptase quantification for anaphylaxis diagnosis and acute infection biomarker analysis.

The company's core offering is a proprietary silicon plasmo-photonic biosensor technology that uses plasmonic interferometric sensors on a micrometer-scale sensing area, capable of detecting multiple critical biomarkers from picoliter-scale analytes. Manufacturing leverages standard CMOS semiconductor processes to produce low-cost, multi-sensor biochips embedded in disposable cartridges, with two flagship diagnostic projects: MultiCare (a 2-year, small-scale project completed in June 2023 that validated plasmo-photonic biosensing as an in-vitro diagnostic device for acute infection analysis) and LOTTO (a higher-sensitivity tryptase detection prototype for rapid anaphylaxis diagnosis). The company has pursued AI/ML partnerships as a stated future capability to integrate personalized test outcomes with patient medical records, demographics, and medical statistics, though no implemented AI product is disclosed.

Bialoom is in pre-commercial stage with no disclosed revenue, customers, pricing, or active distribution channels. The business model centers on future sales of disposable biochip cartridges used with a proprietary point-of-care instrument, targeting institutional healthcare buyers via an enterprise field-sales motion. To date the company has been financed primarily through non-dilutive sources — the EU Horizon 2020 research and innovation programme (Grant Agreement No 888337, SepsiCare) and the Cyprus Research and Innovation Foundation Proof of Concept programme (Grant No CONCEPT/0618/0038, LOTTO) — with operational support from incubators Gravity Ventures / CyRIC and co-development relationships with AMO GmbH and RWTH Aachen.

bialoom firmographics

Firmographics
Name
bialoom
Legal name
bialoom
Website
https://bialoom.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Bialoom is a Nicosia, Cyprus-based deep tech startup developing silicon plasmo-photonic biosensor technology for point-of-care diagnostics of severe infections and anaphylaxis, targeting emergency departments, allergy clinics, and private medical practices. The company is pre-commercial with proof-of-concept validated and grant-funded R&D in progress.
Ownership category
akta.pro rank

bialoom industry classification

Industry
Product category
Point-of-Care Diagnostics
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Laboratory Analytical Instruments (3826), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)

Keywords

  • Point-of-care diagnostics
  • Silicon photonics biosensors
  • Plasmonic biochips
  • In-vitro diagnostic devices
  • Anaphylaxis and sepsis testing

Where bialoom is headquartered

Location

Headquarters

HQ city
Nicosia
HQ country
Cyprus
HQ region
Europe

Offices1 record

Markets served

bialoom business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Disposable Diagnostic Cartridges: Revenue expected from sale of disposable biochip cartridges for point-of-care diagnostics. The company is developing multi-functional biochips capable of quantifying biomarker signatures from patient blood for faster diagnosis and treatment of severe infections.

Go-to-market motion1 record

Marketing channels4 records

bialoom product offering

Product offering

Core offering

Bialoom develops proprietary silicon plasmo-photonic biosensor technology delivered as multi-functional biochips embedded in disposable cartridges capable of quantifying complex biomarker signatures from patient blood. The company targets point-of-care diagnosis of acute infections and anaphylaxis at emergency departments, allergy clinics, hospitals, and private medical practices. Validated programs include MultiCare (acute infections, completed June 2023) and LOTTO (tryptase detection for anaphylaxis).

Product overview

bialoom is a deep tech diagnostics company offering a unified portfolio built around proprietary silicon plasmo-photonic biosensor technology. The core technology powers multi-functional biochips embedded in disposable cartridges capable of quantifying complex biomarker signatures from patient blood. The product portfolio includes two validated diagnostic projects: MultiCare validated the technology for acute infection diagnostics at point of care, while LOTTO demonstrated a prototype for high-sensitivity tryptase detection for anaphylaxis diagnosis. Both products leverage the same underlying platform technology combining silicon photonics, plasmonics, and in-vitro diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

  • MultiCare: In-vitro diagnostic device for analysis of acute infections at the point of care using plasmo-photonic biosensing technology. Small-scale 2-year project completed in June 2023.
  • LOTTO

Products and services

  • MultiCare A plasmo-photonic biosensing in-vitro diagnostic device for analysis of acute infections at the point of care. The MultiCare program validated the underlying biosensor technology, optimized product design for market needs, and established the system proof of concept.
  • LOTTO (Low-cost Optical biochip for diagnosis of anaphylaxis at The poinT Of care) A high-sensitivity tryptase detection prototype system enabling rapid anaphylaxis diagnosis at the point of care, designed for use in emergency departments, allergy clinics, and private medical practices.
  • Silicon Plasmo-Photonic Biosensor Disposable Cartridges Proprietary multi-functional biochips embedded in disposable cartridges that quantify complex biomarker signatures from patient blood, intended to enable faster, evidence-based diagnosis and treatment of severe infections at the point of need.

Quantifiable outcome

  • Point-of-care diagnosis without need for centralized lab equipment

Companies that use bialoom

Customer profile

Segments2 records

Ideal customer profiles2 records

bialoom technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

bialoom partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • AMO GmbHminorStrategic or Co-development PartnerAMO GmbH is a technology partner. Nature of partnership involves collaboration on silicon photonics and biosensor development. AMO is listed as a partner on the company website.
  • RWTH AachenminorStrategic or Co-development PartnerRWTH Aachen University is listed as a partner. The partnership involves research collaboration related to biosensor technology development.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

bialoom competitors and assessment

Company assessment

Direct peers

  • LumiraDx: Point-of-care diagnostics platform company combining microfluidic and immunoassay technologies on a single instrument with disposable test strips. Highly comparable to bialoom's POC, multi-analyte, disposable-cartridge strategy for acute and time-critical indications.
  • T2 Biosystems: Developer of proprietary diagnostic biosensor platforms (T2MR) for sepsis and other bloodstream infections. Directly comparable use case (rapid sepsis diagnostics) and a precedent for a small company commercializing a novel biosensor-based IVD.

Broad incumbents

  • QuidelOrtho: Major IVD player with a deep POC portfolio including Triage and Sofia rapid diagnostics used in emergency departments and clinics. Direct overlap with bialoom's anaphylaxis and acute-infection ED targets, and a likely employer/competitor for its core engineering talent.
  • Abbott Point of Care: Established i-STAT and rapid diagnostics franchise serving emergency departments and physician offices. Represents both a primary competitor in POC and a source of comparable product-development experience via bialoom team member Kyle Hukari's prior role.
  • Cepheid (Danaher): Established molecular diagnostics franchise (GeneXpert) used in hospitals and EDs for rapid syndromic testing including sepsis and infectious disease. Sets the performance and workflow bar bialoom's POC biosensor must match or beat.
  • Roche Diagnostics: Global IVD leader with extensive POC and central-lab immunoassay menus for sepsis, cardiac, and allergy markers. Defines the cost, regulatory, and channel benchmark bialoom must compete against in EDs and allergy clinics.

Emerging players

  • Paragraf: UK-based graphene-based biosensor company; bialoom Senior Scientist Serife Ustuner previously worked at Paragraf on surface functionalization. Comparable as a deep-tech biosensor startup targeting IVD and life-science markets.
  • Abionic: Swiss POC diagnostics company using proprietary nanofluidic biosensor technology for rapid allergy (IgE), sepsis, and other panels. Closely aligned with bialoom on miniaturized, chip-based POC IVDs for anaphylaxis and acute infection.
  • Standard BioTools: Life-science instrumentation company focused on single-cell analysis, qPCR, and protein detection; bialoom's Kyle Hukari previously directed engineering there. Comparable as a developer of consumable-driven analytical instruments using semiconductor-like manufacturing.

Others

  • Mesa Labs: Specializes in critical measurement and sensor-based products including biological indicators and sterilization monitoring. Adjacent as a sensor/measurement instrumentation peer with a similar deep-tech-to-commercial trajectory.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

bialoom financial estimates

Financial estimate

Revenue estimate

Valuation estimate

bialoom leadership team

Management profile

Number of profiles

Profiles8 records

bialoom funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

bialoom M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about bialoom

What does bialoom do?

Bialoom develops proprietary silicon plasmo-photonic biosensor technology delivered as multi-functional biochips embedded in disposable cartridges capable of quantifying complex biomarker signatures from patient blood. The company targets point-of-care diagnosis of acute infections and anaphylaxis at emergency departments, allergy clinics, hospitals, and private medical practices. Validated programs include MultiCare (acute infections, completed June 2023) and LOTTO (tryptase detection for anaphylaxis).

Is bialoom a public or private company?

bialoom is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was bialoom founded?

bialoom was founded in 2018. It employs 1 to 10 people.

Where is bialoom based?

bialoom is headquartered in Nicosia, Cyprus, in the Europe region.

How does bialoom make money?

One revenue line is on record: disposable Diagnostic Cartridges.

Who are bialoom's main competitors?

Direct peers on record are LumiraDx and T2 Biosystems. Broad incumbents are QuidelOrtho, Abbott Point of Care, Cepheid (Danaher) and Roche Diagnostics. Emerging players are Paragraf, Abionic and Standard BioTools. Mesa Labs is listed as an others.

Does bialoom have an API?

No public API is recorded for bialoom.

What industry is bialoom in?

bialoom's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals